Literature DB >> 11234901

Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.

C C Bancroft1, Z Chen, G Dong, J B Sunwoo, N Yeh, C Park, C Van Waes.   

Abstract

Interleukin 8 (IL-8) and vascular endothelial growth factor (VEGF) promote tumor angiogenesis, growth, and metastasis and are coexpressed by human head and neck squamous cell carcinomas (HNSCCs) and a variety of other cancers. The promoters of the IL-8 and VEGF genes contain different recognition sites for transcription factors nuclear factor (NF)-kappaB and activator protein-1 (AP-1), which we showed previously are coactivated in HNSCCs. NF-kappaB and AP-1 may be modulated by the inhibitor kappaB kinase (IKK) and mitogen-activated protein kinase (MAPK) signal pathways, but the contribution of these pathways to expression of IL-8 and VEGF and as potential targets for antiangiogenesis therapy in HNSCC is not known. In this study, we examined the effects of modulation of the MAPK and IKK pathways on expression of IL-8 and VEGF by UM-SCC-9 and UM-SCC-11B cell lines. Interruption of IKK-mediated activation of NF-kappaB by expression of an inhibitor kappaB alpha mutant (IkappaB alphaM) in UM-SCC-9 cells resulted in partial inhibition of expression of IL-8 but not VEGF. Analysis of possible alternative pathways for induction of these genes revealed activation of the MAPK extracellular signal-regulated kinase (ERK1/2) in cell lines UM-SCC-9 and UM-SCC-11B. Basal and tumor necrosis factor-alpha-inducible phosphorylation of ERK1/2 and secretion of IL-8 and VEGF could be specifically inhibited by a MEK inhibitor, U0126. Expression of IL-8 and VEGF in the cell lines was associated with coactivation of both NF-kappaB and AP-1, and U0126 inhibited both NF-kappaB and AP-1 reporter activity in UM-SCC-9 and UM-SCC-11B cells. The ERK pathway appears to contribute to expression of IL-8 and VEGF and transactivation of NF-kappaB as well as AP-1 in HNSCC. Combined inhibition of both MAPK and IKK pathways may be needed for suppression of the signal transduction mechanism(s) regulating VEGF and IL-8 secretion and angiogenesis by human HNSCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11234901

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

Review 1.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  DNA methylome and transcriptome alterations and cancer prevention by triterpenoid ursolic acid in UVB-induced skin tumor in mice.

Authors:  Yuqing Yang; Ran Yin; Renyi Wu; Christina N Ramirez; Davit Sargsyan; Shanyi Li; Lujing Wang; David Cheng; Chao Wang; Rasika Hudlikar; Hsiao-Chen Kuo; Yaoping Lu; Ah-Ng Kong
Journal:  Mol Carcinog       Date:  2019-06-25       Impact factor: 4.784

Review 3.  Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.

Authors:  Josephine Chou; Yu-Ching Lin; Jae Kim; Liang You; Zhidong Xu; Biao He; David M Jablons
Journal:  Head Neck       Date:  2008-07       Impact factor: 3.147

4.  Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.

Authors:  Carter Van Waes; Clint T Allen; Deborah Citrin; David Gius; A Dimetrios Colevas; Nancy A Harold; Susan Rudy; Liesl Nottingham; Christine Muir; Zhong Chen; Anurag K Singh; Janet Dancey; John C Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-30       Impact factor: 7.038

5.  Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

Authors:  Athanassios Argiris; Steve C Lee; Trevor Feinstein; Sufi Thomas; Barton F Branstetter; Raja Seethala; Lin Wang; William Gooding; Jennifer R Grandis; Robert L Ferris
Journal:  Oral Oncol       Date:  2011-09-01       Impact factor: 5.337

6.  MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Authors:  Suresh Mohan; Robert Vander Broek; Sujay Shah; Danielle F Eytan; Matthew L Pierce; Sophie G Carlson; Jamie F Coupar; Jialing Zhang; Hui Cheng; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

7.  The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas.

Authors:  Zhong Chen; Bin Yan; Carter Van Waes
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

8.  Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications.

Authors:  Rifat Hasina; Mark E Whipple; Leslie E Martin; Winston Patrick Kuo; Lucila Ohno-Machado; Mark W Lingen
Journal:  Lab Invest       Date:  2008-02-18       Impact factor: 5.662

9.  Identification of tetranectin as a potential biomarker for metastatic oral cancer.

Authors:  Martha E Arellano-Garcia; Roger Li; Xiaojun Liu; Yongming Xie; Xiaofei Yan; Joseph A Loo; Shen Hu
Journal:  Int J Mol Sci       Date:  2010-09-02       Impact factor: 5.923

10.  NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.

Authors:  Shuichi Fujioka; Jiangong Niu; Christian Schmidt; Guido M Sclabas; Bailu Peng; Tadashi Uwagawa; Zhongkui Li; Douglas B Evans; James L Abbruzzese; Paul J Chiao
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.